GLP-1 medications, such as Ozempic and Wegovy, are injected into the fatty layer beneath the skin to manage blood sugar and aid in weight management. The recommended injection sites include the ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

Experts describe the development of oral GLP-1 medication as a “pivotal” improvement in the accessibility and adherence to obesity drugs. As of February 2026, only Wegovy and Rybelsus are available in ...

Common GLP-1s include semaglutides like Ozempic and Wegovy, and tirzepatides like Zepbound and Mounjaro. These drugs work by mimicking a natural hormone to regulate appetite, blood sugar, and feelings ...

Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. Glucagon-like peptide-1 (GLP-1) agonists are injectable ...

Modern medicine is continually advancing treatment options for many chronic health conditions. For type 2 diabetes, obesity, and weight management, GLP-1 receptor agonists are medications that may ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...

New research reveals that young adults with higher body shame and weight concerns are more likely to consider GLP-1 medications, despite significant side effects, unless buffered by strong body ...

The cost of GLP-1 medications varies widely, ranging from around $199 to over $1,500. Insurance coverage for GLP-1s is more common for diabetes management than for weight loss. Consumers can ...

Citrini Research has named AI-driven workforce changes, restaurant automation, and post-GLP-1 weight management as thematic investment areas to watch in 2026. The firm sees upside in companies that ...